Cellares

Cellares will be exhibiting at the 9th annual CAR-TCR Summit in Boston from Tuesday, September 17th - Friday, September. 20th. Please join us at booth 21 to learn how our Industry 4.0 approach is poised to revolutionize cell therapy manufacturing. Interested in meeting with us? Reach out via the event app or contact us directly at BD@cellares.com. Let's discuss how we can accelerate access to life-saving cell therapies together! #CARTCRSummit #CellTherapy #Biotechnology #CGT

Cellares and Sony Collaboration! 🌟 We are teaming up with Sony to again transform cell therapy manufacturing. The goal of this collaboration is to integrate advanced flow cytometry-based cell analysis and sorting capabilities into the Cell Shuttle. This partnership will leverage technology developed for Sony’s CGX10 Cell Isolation System and may bring enhanced efficiency and scalability to sorting-dependent cell therapy modalities, such as regulatory T cell and hematopoietic stem cell workflows. Potential highlights of this collaboration include: - The ability to sort cells rapidly while achieving high cell purity and viability in an automated and closed system - Online real-time monitoring of cell quality and quantity - Reduced cell therapy manufacturing costs and vein-to-vein times We expect that this integration will set a new standard of performance for clinical and commercial-scale cell therapy manufacturing. Learn more: https://lnkd.in/gGWWmGrT

Please join us at the 9th Annual CAR-TCR Summit, where Cellares CEO and Co-Founder, Fabian Gerlinghaus, will be presenting on Revolutionizing Your Cell Therapy Manufacturing to Avoid the Impending Patient Access Crisis. 🗓️ Date: September 18th ⏰ Time: 5:30 PM ET Don't miss out on this opportunity to learn how our automated cell therapy manufacturing technologies can transform your process, enabling you to meet the total global patient demand for your cell therapy and avoid the impending patient access crisis. 👉 Visit https://lnkd.in/g9UJXJPU to learn more.

Major milestone 🚀 We have completed assembly of the first cGMP Cell Shuttle at our IDMO Smart Factory in Bridgewater, NJ. The first step to enabling the production of up to 100,000 cell therapy doses per year out of this single facility. On the way to fulfilling our mission to provide life-saving cell therapies to patients in need. Learn more: https://lnkd.in/gvC_AZik

Would you like to access enough manufacturing capacity for your cell therapy to treat ALL the patients that need it? Would you like to investigate more indications for your cell therapy to de-risk your pipeline? Would you like to make your cell therapy available globally? Revolutionize your cell therapy manufacturing and meet total patient demand for your life-saving therapies. Our EVP of commercialization, Arturo Araya, will attend this year’s Advanced Therapies Week Europe. Schedule a meeting with Arturo👇 https://lnkd.in/gdbPV_M8 #ATE24 #CellTherapyManufacturing

📢 Important Leadership Announcements 📢 We are pleased to announce the appointment of Justin McAnear as CFO and Jonathan Butler as General Counsel. Justin's impressive background with 10x Genomics, Tesla, Apple, and Johnson & Johnson complements our high growth objectives. Jonathan’s expertise from his time at Lucid Motors and Tesla will be valuable as we progress the company. Their combined experience will help us continue to drive our mission of accelerating access to life-saving cell therapies. Read the full press release to learn more about their inspiring journeys and what they bring to Cellares 👇 https://lnkd.in/gkNWgX58 #Leadership #CellTherapyManufacturing #Celltherapy

Cell therapy manufacturing can feel like a heavy lift because of manufacturing costs and the inability to scale efficiently... and it's costing us big time. The sad truth? People are stuck and dying on waitlists for life-saving therapies. We need to start talking about new ways to scale production and make these treatments accessible. What are the biggest bottlenecks? How can we shake things up in the cell therapy world? I'd like to hear your ideas and experiences—drop them in the comments! 🙌 #CellTherapyManufacturing #CellTherapy #Pharma

We’re honored to announce that we have been selected to participate in the Global Health 2024 initiative! 🌍 Hosted by Reuters, this World Health Day initiative includes a collection of short documentary films featuring leading healthcare innovators. In our film segment, Fabian Gerlinghaus, CEO and Co-Founder of Cellares; Prof. Carl June, cell therapy pioneer, and Bob Levis, CAR-T patient, discuss the history, challenges, and future of CAR-T therapies, and how Cellares’ IDMO Smart Factories, powered by our Cell Shuttles and Cell Qs, can accelerate access to life-saving cell therapies. Watch the full video here 👉 https://lnkd.in/gyxQ5BMZ #WorldHealthDay #GlobalHealth2024 #CellTherapy #Innovation

Big strides in personalized cell therapy! Major pharmaceutical companies are implementing new methods to increase the availability of CAR-T therapies for patients by: ☑ Shortening manufacturing time (Novartis) ☑ Using healthier starting cells (Gilead) ☑ Automating manufacturing with Cellares (Bristol Myers Squibb) “Lynelle Hoch, who leads Bristol Myers Squibb's cell therapy business, said its current focus is on increasing manufacturing capacity. Still, it (BMS) said its time to produce the treatments is trending lower and will be helped by its collaboration with Cellares, a development and manufacturing organization with a fully automated cell therapy production platform.” With the industry's focus on increasing manufacturing capacity and decreasing turnaround times, the future of CAR-T therapies looks promising. Read more about these advancements in the latest Reuters article: https://lnkd.in/ep98CtNF #CellTherapyManufacturing #CellTherapy #Reuters

Financial Times recently published an article discussing the dramatic clinical responses CAR-T therapies are producing in patients with autoimmune diseases. However, manufacturing capacity to treat these large patient populations is an impending challenge: “Only 35,000 lymphoma and leukaemia patients have been treated with CAR-T in the US since its approval seven years ago. In comparison, an estimated 204,000 Americans have systemic lupus erythematosus” Cellares’ integrated and automated manufacturing technology offered through our IDMO can overcome current cell therapy production constraints to meet the total treatment demand of autoimmune patients. Read the full article here: https://lnkd.in/gxs7ssg4